Rhythm Pharmaceuticals, INC Form 4 insider transactions

Rhythm Pharmaceuticals' President and CEO, David P. Meeker, reported the vesting of restricted stock units and a subsequent sale of shares for tax obligations.

Jennifer Kayden Lee, EVP at Rhythm Pharmaceuticals, reported the vesting of 22,612 restricted stock units and a subsequent sale of 9,237 shares to cover tax obligations.

Rhythm Pharmaceuticals' Corporate Controller and CAO, Christopher Paul German, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals, reported the exercise of restricted stock units and the sale of common stock to satisfy tax obligations.

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, reported the vesting of 13,293 restricted stock units and the sale of 4,731 shares for tax obligations.

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, exercised stock options and subsequently sold the acquired common stock for a significant gain.

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, sold 3,350 shares of common stock for $105 per share after exercising stock options at $27.35, pursuant to a pre-arranged trading plan.

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, executed pre-planned sales of common stock following the exercise of stock options.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, exercised stock options and subsequently sold 9,748 shares of common stock for over $1.1 million.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, sold 2,815 shares of common stock on October 28, 2025, following the exercise of stock options.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, exercised stock options and subsequently sold a portion of his common stock holdings.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, executed a pre-planned transaction, exercising stock options and selling an equivalent number of common shares.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, exercised stock options and subsequently sold 4,188 shares under a pre-arranged 10b5-1 plan.

Rhythm Pharmaceuticals' CFO, Hunter C. Smith, sold common stock totaling 28,088 shares in August 2025, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Rhythm Pharmaceuticals' Corporate Controller and CAO, Christopher Paul German, executed pre-planned transactions involving the exercise of stock options and subsequent sale of common stock.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, exercised stock options and immediately sold the acquired common stock as part of a pre-planned trading arrangement.

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, sold 1,520 shares of common stock for $85.93 per share to cover tax withholding related to the vesting of restricted stock units.

Rhythm Pharmaceuticals' Chief Financial Officer, Hunter C. Smith, exercised stock options and subsequently sold a total of 42,120 shares of common stock on July 9, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, exercised stock options and subsequently sold an equivalent number of common shares on July 9, 2025, under a Rule 10b5-1 plan, maintaining his beneficial ownership.

Rhythm Pharmaceuticals' Corporate Controller & CAO, Christopher Paul German, executed a series of transactions on July 9, 2025, involving the exercise of stock options and subsequent sale of common stock under a Rule 10b5-1 trading plan.

Pamela J. Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, executed stock options and simultaneously sold an equivalent number of common shares on July 9, 2025, under a Rule 10b5-1 trading plan.

Rhythm Pharmaceuticals' Chief Financial Officer, Hunter C. Smith, exercised stock options to acquire 6,986 shares of common stock at an exercise price of $6.88 per share.

Rhythm Pharmaceuticals' Chief Scientific Officer, Alastair Garfield, reported the vesting of restricted stock units and a subsequent sale of common stock to cover tax obligations, executed under a Rule 10b5-1 plan.

Camille L. Bedrosian, a Director at Rhythm Pharmaceuticals, Inc., was granted stock options and restricted stock units as part of her compensation, aligning her interests with shareholders.

Rhythm Pharmaceuticals, Inc. Director Jennifer L. Good was granted 7,037 stock options and 4,712 restricted stock units as part of her compensation.

Rhythm Pharmaceuticals, Inc. Director Edward T. Mathers has been granted new stock options and restricted stock units as part of his compensation, aligning his interests with shareholders.

Christophe Jean, a Director at Rhythm Pharmaceuticals, Inc. (RYTM), was granted stock options and restricted stock units as part of his compensation.

Rhythm Pharmaceuticals, Inc. Director Stuart A. Arbuckle was granted 7,037 stock options and 4,712 restricted stock units on June 24, 2025, as part of his compensation.

Lynn A. Tetrault, a Director at Rhythm Pharmaceuticals, Inc., reported the acquisition of stock options and restricted stock units as part of her compensation.

Rhythm Pharmaceuticals, Inc. director David W.J. McGirr was granted 7,037 stock options and 4,712 restricted stock units as part of his compensation, vesting in 2026.